Thats a very good point. The FDA would surely have to show pragmatism here and assess the NDA via an expanded scope that includes usual care scenarios in addition to the Phase 3 results. Blinded trials are not easy to conduct because of known side effects so a measure of discretion would have to be factored in. (I hope)
Thats a very good point. The FDA would surely have to show...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 190 | $20.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.98 | 268 | 2 |
View Market Depth
| Last trade - 09.52am 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable